CALT News and Press, Calliditas Therapeutics AB From 08/18/23

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the ...

Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet PR Newswire SHANGHAI , Aug. 17, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Th...

Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire Filing for full approval of TARPEYO STOCKHOLM , Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE GROUP Key Figures April 1 - June 30, 2023 Net sales amounted...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM , Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced ...

2023-07-20 18:36:07 ET Summary We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales. Despite promising interim data, the market has y...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM , July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Cal...

2023-06-25 05:45:00 ET Summary AstraZeneca may separate its China operations into a standalone company and conduct an IPO in Hong Kong or Shanghai to protect its business from east-west political tensions. Cutia Therapeutics, a Shanghai dermatology company, raised $65 million in a...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM , June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

2023-05-31 12:07:41 ET Summary Shares of Calliditas Therapeutics plunged after the company missed Q1 revenue estimates. The quarter was better than it looks and the company saw record new patient enrollments for Tarpeyo. It was also too early for the recently reported 2-year e...

2023-05-30 06:54:18 ET Summary Patient and Prescriber Uptick: Despite Q1 2023's slightly disappointing earnings, Tarpeyo saw robust growth in new patient enrollments and prescriber numbers. Competitive Edge: Recent Phase 3 DUPLEX FSGS readout from Travere showing non-stat signific...